Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/18/22
Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New YearSeeking Alpha • 12/31/21
Ligand's Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with ChemotherapyBusiness Wire • 12/22/21
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
Ligand Pharmaceuticals (LGND) Beats Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/10/21
Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/22/21